메뉴 건너뛰기




Volumn 12, Issue , 2018, Pages 2293-2300

Inotuzumab ozogamicin: A CD22 mab–drug conjugate for adult relapsed or refractory b-cell precursor acute lymphoblastic leukemia

Author keywords

Acute lymphoblastic leukemia; CD22; Inotuzumab ozogamicin; Monoclonal antibody Drug conjugate; Relapsed refractory

Indexed keywords

BLINATUMOMAB; INOTUZUMAB OZOGAMICIN; TISAGENLECLEUCEL T; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 85057890601     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S150317     Document Type: Review
Times cited : (43)

References (47)
  • 1
    • 41349100708 scopus 로고    scopus 로고
    • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
    • Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–1833.
    • (2008) Blood , vol.111 , Issue.4 , pp. 1827-1833
    • Goldstone, A.H.1    Richards, S.M.2    Lazarus, H.M.3
  • 2
    • 28444490353 scopus 로고    scopus 로고
    • Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
    • Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
    • (2005) Blood , vol.106 , Issue.12 , pp. 3760-3767
    • Rowe, J.M.1    Buck, G.2    Burnett, A.K.3
  • 3
    • 33846869976 scopus 로고    scopus 로고
    • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ ECOG 2993 study
    • Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ ECOG 2993 study. Blood. 2007;109(3):944–950.
    • (2007) Blood , vol.109 , Issue.3 , pp. 944-950
    • Fielding, A.K.1    Richards, S.M.2    Chopra, R.3
  • 4
    • 84924412997 scopus 로고    scopus 로고
    • Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
    • Deangelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015; 29(3):526–534.
    • (2015) Leukemia , vol.29 , Issue.3 , pp. 526-534
    • Deangelo, D.J.1    Stevenson, K.E.2    Dahlberg, S.E.3
  • 5
    • 60949101218 scopus 로고    scopus 로고
    • Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study
    • Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–918.
    • (2009) J Clin Oncol , vol.27 , Issue.6 , pp. 911-918
    • Huguet, F.1    Leguay, T.2    Raffoux, E.3
  • 6
    • 85042937385 scopus 로고    scopus 로고
    • Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
    • Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606–615.
    • (2018) Leukemia , vol.32 , Issue.3 , pp. 606-615
    • Toft, N.1    Birgens, H.2    Abrahamsson, J.3
  • 7
    • 85030548518 scopus 로고    scopus 로고
    • Acute lymphoblastic leukemia: A comprehensive review and 2017 update
    • Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
    • (2017) Blood Cancer J , vol.7 , Issue.6
    • Terwilliger, T.1    Abdul-Hay, M.2
  • 8
    • 84988449072 scopus 로고    scopus 로고
    • Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
    • Maury S, Chevret S, Thomas X, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375(11): 1044–1053.
    • (2016) N Engl J Med , vol.375 , Issue.11 , pp. 1044-1053
    • Maury, S.1    Chevret, S.2    Thomas, X.3
  • 9
    • 84981156388 scopus 로고    scopus 로고
    • New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
    • Farhadfar N, Litzow MR. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016;49:13–21.
    • (2016) Leuk Res , vol.49 , pp. 13-21
    • Farhadfar, N.1    Litzow, M.R.2
  • 10
    • 84885426867 scopus 로고    scopus 로고
    • Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia
    • Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25(6):701–706.
    • (2013) Curr Opin Oncol , vol.25 , Issue.6 , pp. 701-706
    • Hoelzer, D.1
  • 11
    • 84933505636 scopus 로고    scopus 로고
    • Monoclonal antibodies in acute lymphoblastic leukemia
    • Jabbour E, O’Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125(26): 4010–4016.
    • (2015) Blood , vol.125 , Issue.26 , pp. 4010-4016
    • Jabbour, E.1    O’Brien, S.2    Ravandi, F.3    Kantarjian, H.4
  • 14
    • 0030993376 scopus 로고    scopus 로고
    • CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling
    • Tedder TF, Tuscano J, Sato S, Kehrl JH, Cd KJH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481–504.
    • (1997) Annu Rev Immunol , vol.15 , pp. 481-504
    • Tedder, T.F.1    Tuscano, J.2    Sato, S.3    Kehrl, J.H.4    Cd, K.J.H.5
  • 15
    • 79551641737 scopus 로고    scopus 로고
    • Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
    • Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52(2): 325–327.
    • (2011) Leuk Lymphoma , vol.52 , Issue.2 , pp. 325-327
    • Piccaluga, P.P.1    Arpinati, M.2    Candoni, A.3
  • 16
    • 10744229449 scopus 로고    scopus 로고
    • Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
    • Dijoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004; 103(5):1807–1814.
    • (2004) Blood , vol.103 , Issue.5 , pp. 1807-1814
    • Dijoseph, J.F.1    Armellino, D.C.2    Boghaert, E.R.3
  • 17
    • 0027194197 scopus 로고
    • Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
    • Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53(14):3336–3342.
    • (1993) Cancer Res , vol.53 , Issue.14 , pp. 3336-3342
    • Hinman, L.M.1    Hamann, P.R.2    Wallace, R.3    Menendez, A.T.4    Durr, F.E.5    Upeslacis, J.6
  • 18
    • 84939267428 scopus 로고    scopus 로고
    • Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
    • Pt A
    • Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107–116.
    • (2015) Mol Immunol , vol.67 , Issue.2 , pp. 107-116
    • Shor, B.1    Gerber, H.P.2    Sapra, P.3
  • 19
    • 84956957250 scopus 로고    scopus 로고
    • Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    • George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 2016;8(2):135–143.
    • (2016) Immunotherapy , vol.8 , Issue.2 , pp. 135-143
    • George, B.1    Kantarjian, H.2    Jabbour, E.3    Jain, N.4
  • 20
    • 77951648118 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: Results of a phase I study
    • Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–2093.
    • (2010) J Clin Oncol , vol.28 , Issue.12 , pp. 2085-2093
    • Advani, A.1    Coiffier, B.2    Czuczman, M.S.3
  • 21
    • 84860243682 scopus 로고    scopus 로고
    • Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
    • Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933–938.
    • (2012) Cancer Sci , vol.103 , Issue.5 , pp. 933-938
    • Ogura, M.1    Hatake, K.2    Ando, K.3
  • 22
    • 79952095577 scopus 로고    scopus 로고
    • Modern therapy of acute lymphoblastic leukemia
    • Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
    • (2011) J Clin Oncol , vol.29 , Issue.5 , pp. 532-543
    • Bassan, R.1    Hoelzer, D.2
  • 23
    • 79954448903 scopus 로고    scopus 로고
    • Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (Inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
    • Dijoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother Pharmacol. 2011;67(4): 741–749.
    • (2011) Cancer Chemother Pharmacol , vol.67 , Issue.4 , pp. 741-749
    • Dijoseph, J.F.1    Dougher, M.M.2    Evans, D.Y.3    Zhou, B.B.4    Damle, N.K.5
  • 24
    • 84856710962 scopus 로고    scopus 로고
    • The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
    • de Vries JF, Zwaan CM, de Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255–264.
    • (2012) Leukemia , vol.26 , Issue.2 , pp. 255-264
    • de Vries, J.F.1    Zwaan, C.M.2    de Bie, M.3
  • 25
    • 35548931579 scopus 로고    scopus 로고
    • Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
    • Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240–2245.
    • (2007) Leukemia , vol.21 , Issue.11 , pp. 2240-2245
    • Dijoseph, J.F.1    Dougher, M.M.2    Armellino, D.C.3    Evans, D.Y.4    Damle, N.K.5
  • 26
    • 84862786326 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study
    • Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13(4):403–411.
    • (2012) Lancet Oncol , vol.13 , Issue.4 , pp. 403-411
    • Kantarjian, H.1    Thomas, D.2    Jorgensen, J.3
  • 27
    • 84880574025 scopus 로고    scopus 로고
    • Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
    • Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–2736.
    • (2013) Cancer , vol.119 , Issue.15 , pp. 2728-2736
    • Kantarjian, H.1    Thomas, D.2    Jorgensen, J.3
  • 28
    • 85029142692 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: A phase 1/2 study
    • Deangelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–1180.
    • (2017) Blood Adv , vol.1 , Issue.15 , pp. 1167-1180
    • Deangelo, D.J.1    Stock, W.2    Stein, A.S.3
  • 29
    • 84984677465 scopus 로고    scopus 로고
    • Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
    • Kantarjian HM, Deangelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med Overseas Ed. 2016;375(8):740–753.
    • (2016) N Engl J Med Overseas Ed , vol.375 , Issue.8 , pp. 740-753
    • Kantarjian, H.M.1    Deangelo, D.J.2    Stelljes, M.3
  • 30
    • 85041221680 scopus 로고    scopus 로고
    • Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE
    • Jabbour EJ, Deangelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018;124(8):1722–1732.
    • (2018) Cancer , vol.124 , Issue.8 , pp. 1722-1732
    • Jabbour, E.J.1    Deangelo, D.J.2    Stelljes, M.3
  • 31
    • 85045950102 scopus 로고    scopus 로고
    • Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
    • Jabbour E, Ravandi F, Kebriaei P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia. JAMA Oncol. 2018;4(2):230–234.
    • (2018) JAMA Oncol , vol.4 , Issue.2 , pp. 230-234
    • Jabbour, E.1    Ravandi, F.2    Kebriaei, P.3
  • 32
    • 77954839504 scopus 로고    scopus 로고
    • Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
    • Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8): 1840–1845.
    • (2010) Cancer Sci , vol.101 , Issue.8 , pp. 1840-1845
    • Ogura, M.1    Tobinai, K.2    Hatake, K.3
  • 33
    • 84860243682 scopus 로고    scopus 로고
    • Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
    • Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933–938.
    • (2012) Cancer Sci , vol.103 , Issue.5 , pp. 933-938
    • Ogura, M.1    Hatake, K.2    Ando, K.3
  • 34
    • 84875434050 scopus 로고    scopus 로고
    • Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: Results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
    • Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–583.
    • (2013) J Clin Oncol , vol.31 , Issue.5 , pp. 573-583
    • Fayad, L.1    Offner, F.2    Smith, M.R.3
  • 35
    • 85051599508 scopus 로고    scopus 로고
    • Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    • Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2017;28.
    • (2017) Br J Haematol , pp. 28
    • Dang, N.H.1    Ogura, M.2    Castaigne, S.3
  • 36
    • 85021846886 scopus 로고    scopus 로고
    • Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study
    • Kantarjian HM, Deangelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017; 4(8):e387–e398.
    • (2017) Lancet Haematol , vol.4 , Issue.8 , pp. e387-e398
    • Kantarjian, H.M.1    Deangelo, D.J.2    Advani, A.S.3
  • 37
    • 0027478056 scopus 로고
    • Veno-occlusive Disease of the Liver and Multio-rgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients
    • Mcdonald GB, et al. Veno-occlusive Disease of the Liver and Multio-rgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients. Ann Intern Med. 1993;118(4):255.
    • (1993) Ann Intern Med , vol.118 , Issue.4 , pp. 255
    • McDonald, G.B.1
  • 38
    • 0021363719 scopus 로고
    • Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
    • Mcdonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1): 116–122.
    • (1984) Hepatology , vol.4 , Issue.1 , pp. 116-122
    • McDonald, G.B.1    Sharma, P.2    Matthews, D.E.3    Shulman, H.M.4    Thomas, E.D.5
  • 39
    • 0023552434 scopus 로고
    • Venoocclusive disease of the liver following bone marrow transplantation
    • Jones RJ, Lee KSK, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987; 44(6):778–783.
    • (1987) Transplantation , vol.44 , Issue.6 , pp. 778-783
    • Jones, R.J.1    Lee, K.S.K.2    Beschorner, W.E.3
  • 40
    • 79952615903 scopus 로고    scopus 로고
    • Defi-brotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation
    • Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E. Defi-brotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2011;17(4):497–506.
    • (2011) Biology of Blood and Marrow Transplantation , vol.17 , Issue.4 , pp. 497-506
    • Palomo, M.1    Diaz-Ricart, M.2    Rovira, M.3    Escolar, G.4    Carreras, E.5
  • 42
    • 84963563658 scopus 로고    scopus 로고
    • Phase 3 trial of defibrot-ide for the treatment of severe veno-occlusive disease and multi-organ failure
    • Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrot-ide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–1665.
    • (2016) Blood , vol.127 , Issue.13 , pp. 1656-1665
    • Richardson, P.G.1    Riches, M.L.2    Kernan, N.A.3
  • 43
    • 85040318688 scopus 로고    scopus 로고
    • Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review
    • Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449–456.
    • (2018) Bone Marrow Transplant , vol.53 , Issue.4 , pp. 449-456
    • Kebriaei, P.1    Cutler, C.2    de Lima, M.3
  • 44
    • 85014771892 scopus 로고    scopus 로고
    • Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
    • Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med Overseas Ed. 2017;376(9):836–847.
    • (2017) N Engl J Med Overseas Ed , vol.376 , Issue.9 , pp. 836-847
    • Kantarjian, H.1    Stein, A.2    Gökbuget, N.3
  • 45
    • 85041377767 scopus 로고    scopus 로고
    • Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
    • Park JH, Rivière I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med Overseas Ed. 2018;378(5):449–459.
    • (2018) N Engl J Med Overseas Ed , vol.378 , Issue.5 , pp. 449-459
    • Park, J.H.1    Rivière, I.2    Gonen, M.3
  • 46
    • 85032490661 scopus 로고    scopus 로고
    • FDA approves first CAR T therapy
    • Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16(10):669.
    • (2017) Nat Rev Drug Discov , vol.16 , Issue.10 , pp. 669
    • Mullard, A.1
  • 47
    • 85057810889 scopus 로고    scopus 로고
    • August 17, Accessed July 7, 2018
    • Reuters Staff. FDA approves Pfizer’s drug for rare blood cancer; 2017, August 17. Available from: https://in.reuters.com/article/us-pfizer-fda-leukemia-idINKCN1AX2A0. Accessed July 7, 2018.
    • (2017) FDA Approves Pfizer’s Drug for Rare Blood Cancer


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.